FindMyKOL
Clinical trialNCT07573332Not, yet, recruitingPhase 1Interventional

A Safety and Tolerability Study of CC- 97540 (BMS-086353) in Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Patients

NCT07573332 is a phase 1 interventional trial sponsored by University of Texas Southwestern Medical Center. As of 21 Nov 2026, it is not yet recruiting. It studies CC-97540, Cyclophosphamide, Fludarabine and Tocilizumab in AQP4+ NMOSD. The registry lists an enrollment of 5 participants at 1 site in 1 country. The registry lists a start date of 1 Sept 2026 and a primary completion date of 1 Aug 2030.

View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT07573332
FieldValue
Registry IDNCT07573332
StatusNot yet recruiting
PhasePhase 1
Study typeInterventional trial
Lead sponsorUniversity of Texas Southwestern Medical Center
Enrollment5
Registered sites1
Countries1
ConditionsAQP4+ NMOSD
DrugsCC-97540, Cyclophosphamide, Fludarabine and Tocilizumab
Start1 Sept 2026
Primary completion1 Aug 2030
Study completion1 Aug 2031
Last update posted17 Jul 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The goal of this clinical trial is to find out if the investigational medicine BMS-986353 is safe and well tolerated in adults with anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD). NMOSD is a long-term autoimmune condition that affects the optic nerves and spinal cord and can lead to relapses. Most people with NMOSD have antibodies against AQP4, which are linked to future disease activity. The main questions this study aims to answer are: "-" Is CC-97540 (BMS-986353) safe and well tolerated, based on how many participants experience serious side effects that limit dosing (called dose-limiting toxicities)? "-" Does CC-97540 (BMS-986353) show early signs of benefit, based on how many participants no longer have detectable AQP4 antibodies in their blood (called sero-reversion)? Participants are adults aged 18 to 60 years with AQP4 antibody-positive NMOSD who are currently clinically stable on ravulizumab or satralizumab. Approved NMOSD treatments reduce relapses by changing how the immune system works, but they do not remove the cells that make AQP4 antibodies. This study is designed to see whether BMS-986353 can target these cells without the need for long-term immune suppression. Participants will: "-" Receive CC-97540 (BMS-986353) as part of the study "-" Continue their current NMOSD therapy "-" Attend study visits for safety checks, exams, and lab tests

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Texas, United States1 site
  • Ut Southwestern

    Dallas

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexas: 1 siteTX1FloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT07573332

Each answer restates registry values shown on this page.

What is NCT07573332?

NCT07573332 is a phase 1 interventional trial sponsored by University of Texas Southwestern Medical Center. It studies CC-97540, Cyclophosphamide, Fludarabine and Tocilizumab in AQP4+ NMOSD.

Is NCT07573332 recruiting?

As of 21 Nov 2026, it is not yet recruiting.

Who leads NCT07573332?

The registry names Benjamin Greenberg, MD (principal investigator, UT Southwestern) as the overall official.

Where does NCT07573332 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT07573332 study?

The registered drug and biological interventions are CC-97540, Cyclophosphamide, Fludarabine and Tocilizumab.

When is NCT07573332 expected to complete?

The registry lists a primary completion date of 1 Aug 2030 and a study completion date of 1 Aug 2031. The sponsor last updated the record on 17 Jul 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.